Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications-Reference-Cited by-同舟云学术

Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications

Published:2022-03 Issue:3 Volume:28 Page:672-683
ISSN:1080-6040
Container-title:Emerging Infectious Diseases
language:
Short-container-title:Emerg. Infect. Dis.

Author:

Stone Mars,Grebe Eduard,Sulaeman Hasan,Di Germanio Clara,Dave Honey,Kelly Kathleen,Biggerstaff Brad J.,Crews Bridgit O.,Tran Nam,Jerome Keith R.,Denny Thomas N.,Hogema Boris,Destree Mark,Jones Jefferson M.,Thornburg Natalie,Simmons Graham,Krajden Mel,Kleinman Steve,Dumont Larry J.,Busch Michael P.

Publisher

Centers for Disease Control and Prevention (CDC)

Subject

Infectious Diseases,Microbiology (medical),Epidemiology

Reference31 articles.

1. US Food and Drug Administration. In vitro diagnostics EUAs [cited 2021 Aug 11]. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas

2. SARS-CoV-2 seroprevalence survey among 17,971 healthcare and administrative personnel at hospitals, pre-hospital services, and specialist practitioners in the Central Denmark Region.;Jespersen;Clin Infect Dis,2021

3. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.;Pollán;Lancet,2020

4. Estimating the cumulative incidence of SARS-CoV-2 infection and the infection fatality ratio in light of waning antibodies.;Shioda;Epidemiology,2021

5. Low SARS-CoV-2 seroprevalence in blood donors in the early COVID-19 epidemic in the Netherlands.;Slot;Nat Commun,2020

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection of Nucleocapsid Antibodies Associated with Primary SARS-CoV-2 Infection in Unvaccinated and Vaccinated Blood Donors;Emerging Infectious Diseases;2024-08

2. The Elecsys® Anti-SARS-CoV-2 and Elecsys® Anti-SARS-CoV-2 S antibody assays: Differentiating between vaccination and infection, and assessing long-term performance;PLOS ONE;2024-07-18

3. Risk reduction in SARS-CoV-2 infection and reinfection conferred by humoral antibody levels among essential workers during Omicron predominance;2024-06-30

4. Detection of anti-nucleocapsid antibodies associated with primary SARS-CoV-2 infection in unvaccinated and vaccinated blood donors;2024-05-24

5. SARS‐CoV‐2 immunoassays in a predominantly vaccinated population: Performances and qualitative agreements obtained with two analytical approaches and four immunoassays;Vox Sanguinis;2024-04-05